Matt Kapusta, uniQure CEO
UniQure cashes out $10M upfront to get candidate for inherited ALS
Gene therapy player uniQure has signed a new agreement with Apic Bio for its ALS gene therapy.
The biotech said Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.